Ruxolitinib Versus Best Available Therapy in Patients With Steroid-Refractory Acute Graft-Versus-Host Disease: Final Analysis From the Randomized Phase III REACH2 Trial In the phase III ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results